| Literature DB >> 33643871 |
M Shreyamsa1, Anand Mishra1, Pooja Ramakant1, Anit Parihar2, Kul R Singh1, Chanchal Rana3, Sasi Mouli1.
Abstract
BACKGROUND: Ultrasonography (US) is an indispensable tool in the management of thyroid nodules, not only for assessing tumor characteristics but also to assign risk of malignancy and guide in management. Various guidelines and US-based risk stratification systems have been proposed for this purpose. This study aims to compare the diagnostic performances of multimodal US-based risk scores (French TIRADS, TMC-RSS) with conventional US-based scoring systems (Korean TIRADS, ACR-TIRADS, ATA risk stratification).Entities:
Keywords: Multimodal imaging; thyroid; ultrasound; ultrasound risk-stratification
Year: 2021 PMID: 33643871 PMCID: PMC7906102 DOI: 10.4103/ijem.IJEM_675_20
Source DB: PubMed Journal: Indian J Endocrinol Metab ISSN: 2230-9500
US features
| K-TIRADS | A-TIRADS | ATA | F-TIRADS | TMC-RSS | |
|---|---|---|---|---|---|
| Composition | + | + | + | + | + |
| Echogenicity | + | + | + | + | + |
| Orientation | + | + | + | + | + |
| Margins | + | + | + | + | + |
| Calcification | + | + | + | + | + |
| Lymph nodes | + | + | |||
| Elastography | + | + | |||
| Vascularity | + | ||||
| Halo | + | ||||
| Comet tail artifact | + | ||||
| Negative score (for benign features) | + | ||||
| Comments/Criticism | Emphasis on US patterns, therefore difficulty in classification of nodules into risk groups | Technically complex, as numerical values are used | Importance to all suspicious features, but little emphasis on independent risk factors like composition of nodule | Difficulty in reproducibility, requires experience to perform and interpret elastography | A quantitative scoring system which has conventional features with Color Doppler, elastography, and negative scores for benign features |
Cytological and histological characteristics of nodules
| Bethesda category | Histopathology (postoperative) | ||
|---|---|---|---|
| I | 0 (0) | Colloid nodule | 129 (76.8%) |
| II | 140 (83.3%) | NIFTP | 4 (2.4%) |
| III | 2 (1.2%) | PTC | 15 (8.9%) |
| IV | 14 (8.3%) | FVPTC | 7 (4.2%) |
| V | 2 (1.2%) | FTC | 11 (6.5%) |
| VI | 10 (6%) | HCC | 1 (0.6%) |
| MTC | 1 (0.6%) |
US Risk stratification
| K-TIRADS | ACR-TIRADS | ATA risk | F-TIRADS | TMC-RSS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Malignant | Total | Malignant | Total | Malignant | Total | Malignant | Total | Malignant | |
| Low risk | 124 | 9 (7.2%) | 127 | 9 (7%) | 126 | 10 (7.93%) | 132 | 6 (4.5%) | 132 | 3 (2.3%) |
| Intermediate risk | 28 | 12 (42.8) | 27 | 13 (48.1%) | 11 | 1 (9%) | 18 | 13 (72.2%) | 9 | 5 (55.5%) |
| High risk | 16 | 14 (87.5%) | 14 | 13 (92.8%) | 31 | 24 (77.4%) | 18 | 16 (89%) | 27 | 27 (100%) |
| Comments-from our study | On comparison with F-TIRADS or TMC-RSS, there were both risk upgrades and downgrades, details in Table 4 | |||||||||
Risk reassignment
| Risk upgrade | |||||
|---|---|---|---|---|---|
| F-TIRADS | TMC-RSS | ||||
| A-TIRADS → F-TIRADS | ATA → F-TIRADS | A-TIRADS → TMC-RSS | ATA → TMC-RSS | F-TIRADS → TMC-RSS | |
| Low to intermediate | 4 (3) | 6 (3) | 7 (6) | 7 (6) | 2 (1) |
| Intermediate to high | 5 (5) | 1 (0) | 12 (12) | 2 (1) | 9 (9) |
| Comments-from our study | 8 of the 9 nodules upgraded to intermediate risk are malignant on final HPE | 3 of the 7 nodules upgraded to intermediate risk are malignant on final HPE | 18 of the 19 nodules upgraded to intermediate risk are malignant on final HPE | 7 of the 9 nodules upgraded to intermediate risk are malignant on final HPE | 10 of the 11 nodules upgraded to intermediate risk are malignant on final HPE |
| *Total malignant nodules on final HPE in brackets | |||||
| Intermediate to low | 8 (8) | 7 (6) | 12 (12) | 6 (6) | 4 (4) |
| High to intermediate | - | 8 (4) | - | 2 (1) | - |
| High to low | 1 (1) | 2 (2) | 1 (1) | 4 (4) | - |
| Comments-from our study | All 9 nodules downgraded to low risk are benign on final HPE | 8 of the 9 nodules downgraded to low risk are benign on final HPE | All 13 nodules downgraded to low risk are benign on final HPE | All 10 nodules downgraded to low risk are benign on final HPE | All 4 nodules downgraded to low risk are benign on final HPE |
| *Total benign nodules on final HPE in brackets | |||||
HPE=Histopathological examination
Sensitivity and specificity
| Intermediate risk considered benign | Intermediate risk considered malignant | |||
|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | |
| K-TIRADS | 97 | 48.6 | 86.5 | 71.4 |
| ACR-TIRADS | 99.2 | 37.1 | 88.7 | 71.4 |
| ATA | 96.2 | 68.6 | 91 | 74.3 |
| F-TIRADS | 99.2 | 48.6 | 94.7 | 80 |
| TMC-RSS | 99.2 | 68.6 | 96.2 | 88.6 |
Figure 1PPV, NPV, and accuracy

ROC curves and AUC
ROC curves and AUC
| Test Result Variable(s) | Area | Sth. Error | Asymptotic Sig. | Asymptotic 95% Confidence Interval | |
|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||
| K-TIRADS | 0.789 | 0.048 | 0.000 | 0.695 | 0.884 |
| A-TIRADS | 0.801 | 0.048 | 0.000 | 0.707 | 0.895 |
| ATA | 0.826 | 0.046 | 0.000 | 0.736 | 0.917 |
| F-TIRADS | 0.874 | 0.041 | 0.000 | 0.792 | 0.955 |
| TMC-RSS | 0.924 | 0.033 | 0.000 | 0.860 | 0.988 |